1. Available at HIV/DrugStrategies.html

2. Gordon EJ, Myers KJ, Dougherty JP, Rosen H, Ron Y. Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 1995;62(2):153-160.

3. Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996;157(11):4986-4995

4. Available at

5. Myers S, Baker A. Drug discovery—an operating model for a new era. Nature Biotechnology 2001;19:727-730

6. Available at 20040317.asp

7. Roth BD. The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Prog Med Chem 2002;40:1-22

8. Available at 2003363.html

9. Winslow R. The birth of a blockbuster: lipitor's route out of the lab. New York Times. January 24, 2000

10. Lieberman R. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther 2004;11(6):501-506

11. Butcher EC, Berg EL, Kunkel EJ. Systems biology in drug discovery. Nat Biotechnol 2004 0ct;22(10):1253-1259

12. Lawrence CE. Acumen. J Sciences 2003;1:23

13. Lindsay MA. Target discovery. Nat Rev Drug Discovery 2003; 2:831-838

14. Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields S. Protein analysis on a proteomic scale. Nature 2003;422(6928):208-215

15. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs—will they model the next 100? Nat Rev Drug Discov 2003;2(1):38-51

16. Sachse C, Krausz E, Kronke A, Hannus M, Walsh A, Grabner A, Ovcharenko D, Dorris D, Trudel C, Sonnichsen B, Echeverri CJ. High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: Functional genomics investigations of biological pathways. Methods Enzymol 2005;392:242-277

17. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V, Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V, Limmer S, Manoharan M, Vornlocher HP. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173-178

18. Fougerolles A, Manoharan M, Meyers R, Vornlocher HP. RNA interference in vivo: Toward synthetic small inhibitory RNA-based therapeutics. Methods Enzymol 2005;392:278-296

19. Thomas FJ, McLeod HL, Watters JW. Pharmacogenomics: The influence of genomic variation on drug response. Curr Top Med Chem 2004;4(13):1399-1409

20. Harrington CA, Rosenow C, Retief J. Monitoring gene expression using DNA microarrays. Curr Opin Microbiol 2000;3(3): 285-291

21. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science 2000;289(5485): 1760-1763

22. Yang Y, Blomme EA, Waring JF. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem Biol Interact 2004;150(1):71-85

23. Templin MF, Stoll D, Schwenk JM, Potz O, Kramer S, Joos TO. Protein microarrays: promising tools for proteomic research. Proteomics 2003;3(11):2155-2166

24. Available at

25. Available at

26. Griffiths AD. Production of human antibodies using bacteriophage. Curr Opin Immunol 1993;5(2):263-267

27. He M, Taussig MJ. Ribosome display: cell-free protein display technology. Brief Funct Genomic Proteomic 2002;1(2):204-212.

28. Wernerus H, Stahl S. Biotechnological applications for surface-engineered bacteria. Biotechnol Appl Biochem 2004;40(Pt 3): 209-228

29. Verhoeyen M, Milstein C, Winter G. Reshaping human antibodies: grafting an antilysozyme activity. Science 1988;239(4847): 1534-1536

30. Available at (Fleming's dish of penecillin production)

31. Available at

32. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 1999;27(4):397-420.

33. Preziosi P. Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? Nat Rev Drug Discovery 2004;3(6):521-526

34. Available at 58_02.html

35. Available at 200221

36. Available at

37. Hodgson J. ADMET—turning chemicals into drugs. Nature Biotech 2001;19:722-726.

38. Available at

39. Carroll SF. Development partnerships—accelerating product development through collaborative programs. BioProc Intl 2003:48-53.

40. King J. Today's drug discovery: unlocking greater potential. R&D Directions 2004, 10(2):28-39

41. Ernst & Young. Resurgence: Global Biotechnology Report 2004.

Was this article helpful?

0 0
Outsourcing Cheat Sheet

Outsourcing Cheat Sheet

Download this Outsourcing Guide And Discover 10 Tasks You Can Outsource Today. Leverage Your Time And Start Using The Power of Outsourcing. Inside this guide, you'll discover: 10 tasks you can outsource today. Where to outsource your tasks including websites. What to look for when outsourcing. Websites where you can outsource design, writing and programming plus much, much more.

Get My Free Ebook

Post a comment